Edvince is open for partnering discussions. Our strategy is to find a competent partner after completion of the phase 1/2 trial with the capacity to develop and commercialize the product to the benefit of patients suffering from subarachnoid hemorrhage.

For further information, please contact CEO Jan Alenfall:

Jan Alenfall, CEO
+46 709 31 51 15
[email protected]